Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Concomitant inactivation of the p53- and pRB- functional pathways predicts resistance to DNA damaging drugs in breast cancer in vivo.
Knappskog S, Berge EO, Chrisanthar R, Geisler S, Staalesen V, Leirvaag B, Yndestad S, de Faveri E, Karlsen BO, Wedge DC, Akslen LA, Lilleng PK, Løkkevik E, Lundgren S, Østenstad B, Risberg T, Mjaaland I, Aas T, Lønning PE. Knappskog S, et al. Among authors: lokkevik e. Mol Oncol. 2015 Oct;9(8):1553-64. doi: 10.1016/j.molonc.2015.04.008. Epub 2015 May 8. Mol Oncol. 2015. PMID: 26004085 Free PMC article.
Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: a randomised, placebo-controlled study.
Geisler J, Lønning PE, Krag LE, Løkkevik E, Risberg T, Hagen AI, Schlichting E, Lien EA, Ofjord ES, Eide GE, Polli A, di Salle E, Paolini J. Geisler J, et al. Among authors: lokkevik e. Eur J Cancer. 2006 Nov;42(17):2968-75. doi: 10.1016/j.ejca.2006.07.005. Epub 2006 Sep 11. Eur J Cancer. 2006. PMID: 16963261 Clinical Trial.
Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer.
Knappskog S, Chrisanthar R, Løkkevik E, Anker G, Østenstad B, Lundgren S, Risberg T, Mjaaland I, Leirvaag B, Miletic H, Lønning PE. Knappskog S, et al. Among authors: lokkevik e. Breast Cancer Res. 2012 Mar 15;14(2):R47. doi: 10.1186/bcr3147. Breast Cancer Res. 2012. PMID: 22420423 Free PMC article. Clinical Trial.
MDM2 promoter SNP344T>A (rs1196333) status does not affect cancer risk.
Knappskog S, Gansmo LB, Romundstad P, Bjørnslett M, Trovik J, Sommerfelt-Pettersen J, Løkkevik E; Norwegian Breast Cancer Group trial NBCG VI; Tollenaar RA, Seynaeve C, Devilee P, Salvesen HB, Dørum A, Hveem K, Vatten L, Lønning PE. Knappskog S, et al. Among authors: lokkevik e. PLoS One. 2012;7(4):e36263. doi: 10.1371/journal.pone.0036263. Epub 2012 Apr 30. PLoS One. 2012. PMID: 22558411 Free PMC article.
18 results